Insights

New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate

The 2 companies plan to submit BNT162b2 for emergency use authorisation in the very near future.
The post New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate appeared first on Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

A health worker drug testing in a lab to find 'covid-19 vaccine' representing covid shares

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.

In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.

That rate, meanwhile, is higher than the 90%-plus demonstrated in the interim analysis of trial data published last week by Pfizer and BioNTech.

With this fresh data, the two companies can now submit BNT162b2 to the United States Food and Drug Administration for emergency use authorisation (EUA), which Pfizer said they planned to do “within days”. The vaccine would be cleared for use with an EUA.

“Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages,” BioNTech CEO Ugur Sahin was quoted as saying.

“We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far, and look forward to sharing further details with the regulatory authorities.”

The 2 companies say they expect to be able to produce up to 50 million doses of their vaccine by the end of this year, and as many as 1.3 billion by the close of 2021.

Both Pfizer and BioNTech’s stocks were on the rise in late-morning US trading Wednesday. Pfizer was up 1.7%, outpacing the S&P 500 Index‘s (INDEXSP: .INX) 0.2% gain, and BioNTech had leaped ahead by 4.5%.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!